Should patients with HR+/HER2− breast cancer and 1–2 positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?

Among patients with HR+/HER2− breast cancer with no other high-risk features, a limited sentinel node disease burden is unlikely to predict a large enough overall nodal burden to qualify for adjuvant abemaciclib. A multi-disciplinary discussion weighing the morbidity of axillary dissection and the potential benefit of abemaciclib is critical.